Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L. (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga, José (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  
2.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (START Madrid, Centro Integral Oncológico Clara Campal) ; Seoane, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Virgen del Rocío, Sevilla, Spain) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M. (Eli Lilly and Company) ; Baselga, Jose (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  

Vegeu també: autors amb noms similars
1 Baselga, J.
1 Baselga, JM.
2 Baselga, Jose
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.